Overview

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and pharmacodynamics of three different doses of MK-8931, a ß-secretase inhibitor, in participants with mild to moderate Alzheimer's Disease (AD).
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.